FDA Speeds Up Approvals for Lab Test Devices
Published Date: 5/1/2026
Notice
Summary
The FDA wants to make it easier for some medical devices used in toxicology tests by removing the need for a special pre-approval process. This change could speed up how these devices get to market and might save money for makers and users. The FDA is asking for your thoughts by June 30, 2026, before making a final decision.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
510(k) Exemption for Toxicology Tests
FDA intends to exempt certain Class II clinical toxicology test system devices from the 510(k) premarket notification when they are intended for Federal drug testing programs. If finalized, regulated industry will no longer need to submit 510(k) submissions for those listed devices, reducing the time and private costs businesses now spend preparing 510(k)s.
Exemptions Subject to Limits and Labeling
Even if exempted from 510(k), these devices remain subject to the general limitations in 21 CFR 862.9 and the proposed partial limitation that the test system be intended for employment and insurance testing and include labeling stating it is intended solely for employment and insurance testing. Manufacturers must still submit a 510(k) before marketing if a device exceeds those limitations.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20503, Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction
The FDA fixed a previous announcement about Oxandrin tablets (2.5 mg and 10 mg) being pulled from the market due to safety or effectiveness concerns. This update confirms that not only the original drug but also several generic versions were withdrawn and removed from the official drug list. Patients, doctors, and drug makers should note these changes, which affect availability and prescribing options immediately.
Previous / Next Documents
Previous: 2026-08496, Agency Information Collection Activities: Proposed Collection; Comment Request
SAMHSA is updating the annual report form for the PATH program, which helps states and territories support people transitioning from homelessness. This change affects all PATH grant recipients and aims to make reporting clearer and easier, without adding extra costs or time. Comments are open now, so stakeholders can share ideas before the January 31 deadline for submitting reports.
Next: 2026-08500, Combined Notice of Filings #1
The Federal Energy Regulatory Commission got a bunch of new filings from energy companies like solar farms and power plants. These filings include status updates, tariff changes, and complaints that could affect energy rates and operations soon. If you’re involved in energy or just curious, keep an eye on deadlines for comments mostly due by mid-May 2026.